Global Blood Therapeutics is developing novel, small-molecule therapeutics to treat severe, non-malignant blood disorders. The company’s lead candidate, GBT440, is a potential disease‑modifying therapy for sickle cell disease and has shown promising preclinical results. GBT is initiating a Phase I/II clinical trial for GBT440 and will use the new capital to advance that program. The firm is also advancing pipeline research programs targeting hereditary angioedema and hypoxic cardiopulmonary disorders. Global Blood Therapeutics is led by CEO Ted W. Love and is based in South San Francisco. The company intends the financing to support progression of GBT440 into clinical development and to fund broader research efforts. Global Blood Therapeutics is a product-focused biotech building a pipeline of orally available small-molecule drugs that change the shapes of key blood proteins using its SHAPE Platform. Its lead program targets sickle cell disease (SCD), aiming to address the underlying hemoglobin mutation that causes red blood cell "sickling." Sickle cell disease affects roughly 100,000 patients in the United States and more than 15 million worldwide, underscoring the global need the company intends to address. The SHAPE Platform combines advanced computational biology and protein-ligand modeling with medicinal chemistry and empirical screening focused on allosteric modulation to discover potent, orally available compounds with rapid onset and the potential for high efficacy and reduced toxicity. The company was launched by Third Rock Ventures and assembled a leadership team including CEO Mark A. Goldsmith, CSO Brian Metcalf, and CTO Craig Muir alongside scientific founders from UCSF. At formation it secured a $40.7 million Series A financing to advance discovery and development of its SCD program and broader pipeline for severe genetic blood diseases.

Total raised

$89M

Funding rounds

2

Latest round

Series B

Latest activity

Jan 2015